Status:
COMPLETED
ATAC - Endometrial Sub-Protocol
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
45+ years
Phase:
PHASE3
Brief Summary
To compare the difference between the ARIMIDEX group and the tamoxifen group in the incidence of abnormal endometrial histological findings arising after treatment has commenced.
Eligibility Criteria
Inclusion
- Patients eligible for entry into the main ATAC trial (1033IL/0029)
- Not received any previous tamoxifen, for whatever reason
- Not undergone a hysterectomy and do not have a hysterectomy planned within the next 6 years
- No previous endometrial ablation
Exclusion
- Excluded from entry into the main ATAC trial (1033IL/0029). As detailed in Section 4.4 of the main ATAC trial (1033IL/0029)
Key Trial Info
Start Date :
June 1 1997
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
285 Patients enrolled
Trial Details
Trial ID
NCT00814125
Start Date
June 1 1997
End Date
December 1 2005
Last Update
May 1 2009
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.